Lupin Limited gets approval for Luforbec 100/6 µg pMDI in UK
Lupin Limited said that its subsidiary Lupin Healthcare (UK) has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Luforbec (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pressurized metered dose inhaler (pMDI).
Vinita Gupta – CEO of Lupin Limited said: “We are truly delighted to receive the first marketing authorization for generic Fostair 100/6 µg pMDI in the UK. This is an important milestone for our respiratory franchise as we expand our product offering across the globe.
“At Lupin, we remain committed to serving patients suffering from respiratory diseases with quality and cost-effective treatment.”
Luforbec 100/6 µg pMDI is the first branded generic of Fostair (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pMDI, said the Indian pharma company. It is indicated in the UK for asthma treatment and also for the symptomatic treatment of people having severe chronic obstructive pulmonary disease (COPD).
Thierry Volle – President – EMEA, Lupin Limited said: “The approval of Luforbec 100/6 µg pMDI is a pivotal milestone for the UK and a welcome step for Lupin as we draw on our strong expertise in inhalation research and development and expand our respiratory portfolio.
“We are proud to support healthcare providers and patients by continuing to invest in specialized treatments for chronic diseases.”